Alzamend Neuro, Inc. - Common Stock (ALZN)

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Alzamend Neuro teams up with QMENTA for five AL001 Phase 2 trials at Mass General, targeting Alzheimer's, PTSD, bipolar disorder, and more.

Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and reduced systemic side effects.

Alzamend Neuro will begin its first Phase 2 trial of AL001 in 2025, using advanced imaging to study lithium distribution and optimize treatment efficacy.

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Alzamend Neuro developed a head coil for high-resolution brain imaging in Phase 2 trials, aiming to optimize lithium dosing for neurological conditions.

Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects.

Alzamend Neuro completed a Phase 2A study on AL001, identifying a safe lithium dose for Alzheimer's patients. The company plans further trials comparing brain lithium levels in Alzheimer's and other conditions.